DK1393277T3 - Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser - Google Patents

Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser

Info

Publication number
DK1393277T3
DK1393277T3 DK02736994T DK02736994T DK1393277T3 DK 1393277 T3 DK1393277 T3 DK 1393277T3 DK 02736994 T DK02736994 T DK 02736994T DK 02736994 T DK02736994 T DK 02736994T DK 1393277 T3 DK1393277 T3 DK 1393277T3
Authority
DK
Denmark
Prior art keywords
inhibitors
kappa
eye disorders
treat eye
disorders
Prior art date
Application number
DK02736994T
Other languages
English (en)
Inventor
Daniel A Gamache
John M Yanni
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DK1393277T3 publication Critical patent/DK1393277T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02736994T 2001-05-21 2002-05-17 Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser DK1393277T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29249501P 2001-05-21 2001-05-21

Publications (1)

Publication Number Publication Date
DK1393277T3 true DK1393277T3 (da) 2006-10-30

Family

ID=23124921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02736994T DK1393277T3 (da) 2001-05-21 2002-05-17 Anvendelse af NF-Kappa-B inhibitorer til behandling af öjentörhedslidelser

Country Status (17)

Country Link
US (1) US6696453B2 (da)
EP (1) EP1393277B1 (da)
JP (1) JP2004527578A (da)
CN (1) CN1509462A (da)
AT (1) ATE333273T1 (da)
AU (1) AU2002309963B2 (da)
BR (1) BR0209965A (da)
CA (1) CA2447883A1 (da)
CY (1) CY1105220T1 (da)
DE (1) DE60213230T2 (da)
DK (1) DK1393277T3 (da)
ES (1) ES2263785T3 (da)
MX (1) MXPA03010632A (da)
PL (1) PL367286A1 (da)
PT (1) PT1393277E (da)
WO (1) WO2002095704A1 (da)
ZA (1) ZA200308769B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
CN112263672A (zh) * 2020-11-04 2021-01-26 武汉益承生物科技有限公司 一种p55pik抑制剂在制备干眼治疗药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4996209A (en) 1988-06-20 1991-02-26 Alcon Laboratories, Inc. Ophthalmic antiinflammatory compositions comprising S(+)-flurbiprofen
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
DE4028906A1 (de) 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
JPH07508716A (ja) 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
FR2718441B1 (fr) 1994-04-07 1996-06-28 Bioxytech Nouveaux composés de structure benzisoséléna-zoline et -zine, leur procédé de préparation et leurs applications thérapeutiques.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6020351A (en) 1995-08-14 2000-02-01 Oxigene, Inc. Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6100299A (en) 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
PT1037627E (pt) * 1998-07-14 2001-11-30 Alcon Lab Inc Utilizacao do acido 11-(3-dimetilaminopropilideno)-6,11-dihidrodibenz¬b,e|oxepin-2-acetico e seus sais derivados farmaceuticamente aceitaveis para a producao de um medicamento para o tratamento de doencas inflamatorias oftalmicas nao-alergicas e para a prebencao da neovascularizacao ocular
WO2000043000A1 (en) 1999-01-20 2000-07-27 Kyowa Hakko Kogyo Co., Ltd. Proteasome inhibitors
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
ATE270268T1 (de) 1999-04-27 2004-07-15 Novartis Pharma Gmbh 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren

Also Published As

Publication number Publication date
CY1105220T1 (el) 2010-03-03
ATE333273T1 (de) 2006-08-15
WO2002095704A1 (en) 2002-11-28
ES2263785T3 (es) 2006-12-16
WO2002095704A9 (en) 2003-02-27
ZA200308769B (en) 2005-01-26
US6696453B2 (en) 2004-02-24
MXPA03010632A (es) 2004-03-09
JP2004527578A (ja) 2004-09-09
AU2002309963B2 (en) 2007-03-01
CN1509462A (zh) 2004-06-30
EP1393277B1 (en) 2006-07-19
PT1393277E (pt) 2006-09-29
BR0209965A (pt) 2004-04-06
US20030008854A1 (en) 2003-01-09
WO2002095704A8 (en) 2003-09-18
PL367286A1 (en) 2005-02-21
EP1393277A1 (en) 2004-03-03
DE60213230T2 (de) 2006-11-23
DE60213230D1 (de) 2006-08-31
CA2447883A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
AU2002305756A8 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
DK3167872T3 (da) Fremgangsmåder til behandling af inflammationsmedierede tilstande i øjet
ATE318812T1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
TR200401862T4 (tr) Tolerans ve bağımlılığı tedavi etmek için metabotropik glutamat reseptör antagonistleri.
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
NO20013493D0 (no) Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DK1051187T3 (da) Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1744736T3 (da) Fremgangsmåde til behandling af problemer med tørre øjne og uveitis
MXPA03010632A (es) Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos.
DK1579859T3 (da) Anvendelse af N-(2-arylpropionyl)-sulfonamider til behandling af rygmarvsskader
DK1500395T3 (da) Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser
DK1150682T3 (da) Ubichinon Qn til behandling af migrænesmerter